AbbVie and Genmab reported Phase 3 success for Epkinly (t-cell engager) in diffuse large B-cell lymphoma, with the Epkinly plus lenalidomide regimen reducing the risk of progression or death by 60% versus the R-GemOx regimen based on trial censoring rules. The Epcore DLBCL-4 trial met its primary endpoint in a second-line population. The companies did not provide overall survival results in the June release, while noting that safety was consistent with prior knowledge of the individual agents. The outcome follows earlier monotherapy setbacks in Epcore DLBCL programs, which had weakened investor confidence. Analyst commentary cited in the report suggested the latest readout increases optimism ahead of additional Epcore trials, including a high-stakes first-line combination program later on the calendar.